Trial · NCT07494565
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
NCT07494565, Phase 2, Recruiting, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL. Trials, record NCT07494565. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07494565
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
- NCT number
- NCT07494565
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive
- Interventions
- Celecoxib Combined with R-CHOP, R-CHOP
- First posted
- 2026-03-27
- Last updated
- 2026-07-22
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response Rate (CRR) | At the end of Cycle 2, 4, and 6 (each cycle is 21 days) | |
| Secondary | ORR [PR + CR] | At the end of Cycle 2, 4, and 6 (each cycle is 21 days) | Overall Response Rate (ORR \[PR + CR\]) |
| Secondary | OS | Participants were followed every 4 weeks for survival until death, lost to follow-up or study closure (approximately 12 months after the last patient ended treatment). | Overall Survival (OS) |
| Secondary | EFS | From date of randomization until the date of first documented disease progression, relapse after CR, death from any cause, or initiation of new treatment for residual lesions after initial therapy, whichever came first, assessed up to 2 years. | Event-Free Survival (EFS) |
| Secondary | PFS | From date of randomization until the date of first documented disease progression, relapse after CR, death from any cause, whichever came first, assessed up to 2 years. | Progression-Free Survival (PFS) |
| Secondary | DoR | DoR was assessed every 4 weeks from the date of first documented response (CR or PR) until disease progression, death, or study closure (approximately 12 months after last patient ended treatment). | Duration of Response (DoR) |
| Secondary | TTP | TTP was assessed every 4 weeks until disease progression, death, or study closure （approximately 12 months after last patient ended treatment). | Time to Progression (TTP) |
| Secondary | Incidence of Adverse events | Day 1 and Day 21 of each cycle (each cycle is 21 days), through completion of 6 cycles, and 30 days after the last dose of study treatment. | Incidence, severity, and relationship to study treatment of adverse events, graded according to NCI-CTCAE version 5.0. |
| Other | Exploratory Objectives | Assessment every 2 cycles (1 cycle = 21 days) | Correlation of NGS-guided gene mutations, ctDNA, serum metabolomics, and lipidomics profiles with efficacy endpoints including CR, DFS, ORR, EFS, PFS, and OS. Correlation of baseline levels of CD5 expression, p-STAT3, FOXO3a/FOXO4, ABCC1 and other proteins with treatment efficacy. Changes in patient-reported outcomes from baseline assessed using EORTC QLQ-C30, EQ-5D-5L, and FACT-LymF. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07494565
GET https://conductscience.org/api/trials/v1/NCT07494565/registered